• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Brandicourt Olivier

    5/2/25 4:28:47 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PCVX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    BRANDICOURT OLIVIER

    (Last) (First) (Middle)
    C/O VAXCYTE, INC.
    825 INDUSTRIAL ROAD, SUITE 300

    (Street)
    SAN CARLOS CA 94070

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Vaxcyte, Inc. [ PCVX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/01/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $35.24 05/01/2025 A 40,113 (1) 05/01/2035 Common Stock 40,113 $0 40,113 D
    Explanation of Responses:
    1. Option shall vest over 36 months, 1/3 of which will vest on May 1, 2026 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.
    Remarks:
    Olivier Brandicourt, by /s/ Peter N. Efremenko, Attorney-In-Fact 05/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PCVX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PCVX

    DatePrice TargetRatingAnalyst
    4/22/2025Overweight
    Cantor Fitzgerald
    12/20/2024$135.00Buy
    Goldman
    12/7/2023$69.00Buy
    Mizuho
    4/18/2023Outperform
    TD Cowen
    1/3/2023$52.00 → $58.00Buy
    Needham
    12/15/2022$66.00Buy
    Guggenheim
    11/17/2022$69.00Buy
    BTIG Research
    12/29/2021$50.00Buy
    Jefferies
    More analyst ratings

    $PCVX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

      -- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Three-Dose Immunization Series Expected in Mid-2026, With Complete Booster Data Up to Nine Months Later -- -- Company Expects to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- Announced VAX-XL, Third-Generation Pneumococcal Conjugate Vaccine Candidate Desig

      5/7/25 4:01:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

      SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors. "We are thrilled to welcome Olivier to Vaxcyte's Board of Directors," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "He brings a wealth of biopharmaceutical expertise, with significant experience in commercial strategy and execution within the global vaccine market.

      5/1/25 8:00:29 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

      -- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formu

      3/31/25 7:00:00 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.

      SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      5/15/25 4:51:54 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Vaxcyte Inc.

      10-Q - Vaxcyte, Inc. (0001649094) (Filer)

      5/7/25 4:23:38 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vaxcyte, Inc. (0001649094) (Filer)

      5/7/25 4:03:56 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

      SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      11/14/24 5:46:11 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

      SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      11/14/24 2:53:06 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

      SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      11/12/24 10:34:18 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Financials

    Live finance-specific insights

    See more
    • Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

      -- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formu

      3/31/25 7:00:00 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

      SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company's 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® in healthy infants. To participate in the conference call, p

      3/30/25 5:00:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

      SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2024 after market close on February 25, 2025. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update. To participate in the conference call, please dial 800-225-9448 (domestic) or 203-518-9708 (international) and refer to conference ID PCVXQ424. A live webcast

      2/12/25 4:05:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Vaxcyte

      Cantor Fitzgerald initiated coverage of Vaxcyte with a rating of Overweight

      4/22/25 7:35:12 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Vaxcyte with a new price target

      Goldman initiated coverage of Vaxcyte with a rating of Buy and set a new price target of $135.00

      12/20/24 7:47:04 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho initiated coverage on Vaxcyte with a new price target

      Mizuho initiated coverage of Vaxcyte with a rating of Buy and set a new price target of $69.00

      12/7/23 7:01:04 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Leadership Updates

    Live Leadership Updates

    See more
    • Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

      SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors. "We are thrilled to welcome Olivier to Vaxcyte's Board of Directors," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "He brings a wealth of biopharmaceutical expertise, with significant experience in commercial strategy and execution within the global vaccine market.

      5/1/25 8:00:29 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Appoints John Furey to Board of Directors

      SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Board of Directors. "We are thrilled to welcome John to Vaxcyte's Board of Directors and look forward to benefiting from his wealth of biopharmaceutical and vaccine expertise, including the manufacture, supply and commercialization of pneumococcal conjugate vaccines (PCVs)," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "As we continue to progress our PCV candidates, VAX-24

      7/2/24 8:30:00 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Appoints Whitney Jones as Chief People Officer

      -- Ms. Jones Joins Vaxcyte With Over 20 Years of Experience Leading People and Culture Strategies Across Multiple Industries -- SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Whitney Jones as Chief People Officer. Ms. Jones will lead Vaxcyte's human resources strategy and operations, including people and culture, talent acquisition and management, learning and development, total rewards and employee engagement. "At Vaxcyte, we are proud to cultivate a culture that values coll

      1/16/24 4:01:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Brandicourt Olivier

      4 - Vaxcyte, Inc. (0001649094) (Issuer)

      5/2/25 4:28:47 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Brandicourt Olivier claimed no ownership of stock in the company (SEC Form 3)

      3 - Vaxcyte, Inc. (0001649094) (Issuer)

      5/2/25 4:27:02 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Dhaliwal Harpreet S. claimed ownership of 36,083 shares (SEC Form 3)

      3 - Vaxcyte, Inc. (0001649094) (Issuer)

      4/25/25 4:13:50 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care